Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT02625623 is registered in ClinicalTrials.gov with EMD Serono Research & Development Institute, Inc. as lead sponsor.

NCT NCT02625623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02625623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 28, 2015
Completion date
November 13, 2019
Enrollment
371 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer third line, unresectable, recurrent, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma